REVIEW

Revisiting blood transfusion and predictors of outcome in cardiac surgery patients: a concise perspective [version 1; peer review: 2 approved]

Carlos E Arias-Morales¹ , Nicoleta Stoicea¹, Alicia A Gonzalez-Zacarias¹, Diana Slawski², Sujatha P. Bhandary², Theodosios Saranteas³, Eva Kaminiotis³, Thomas J Papadimos²

¹Department of Anesthesiology, The Ohio State University Wexner Medical Center, Columbus, OH, USA

²College of Medicine and Life Sciences, The University of Toledo, Toledo, OH, USA

³Second Department of Anesthesiology, School of Medicine, University of Athens, Athens, Greece

V1 First published: 20 Feb 2017, 6(F1000 Faculty Rev):168
<https://doi.org/10.12688/f1000research.10085.1>

Latest published: 20 Feb 2017, 6(F1000 Faculty Rev):168
<https://doi.org/10.12688/f1000research.10085.1>

Abstract

In the United States, cardiac surgery-related blood transfusion rates reached new highs in 2010, with 34% of patients receiving blood products. Patients undergoing both complex (coronary artery bypass grafting [CABG] plus valve repair or replacement) and non-complex (isolated CABG) cardiac surgeries are likely to have comorbidities such as anemia. Furthermore, the majority of patients undergoing isolated CABG have a history of myocardial infarction. These characteristics may increase the risk of complications and blood transfusion requirement. It becomes difficult to demonstrate the association between transfusions and mortality because of the fact that most patients undergoing cardiac surgery are also critically ill. Transfusion rates remain high despite the advances in perioperative blood conservation, such as the intraoperative use of cell saver in cardiac surgery. Some recent prospective studies have suggested that the use of blood products, even in low-risk patients, may adversely affect clinical outcomes. In light of this information, we reviewed the literature to assess the clinical outcomes in terms of 30-day and 1-year morbidity and mortality in transfused patients who underwent uncomplicated CABG surgery.

Keywords

blood transfusion, cardiopulmonary bypass, cardiac surgery, length of stay, mortality

Open Peer Review

Approval Status

	1	2
version 1
20 Feb 2017		

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Fausto Biancari**, Department of Surgery, Oulu University Hospital, Oulu, Finland
2. **Nina A Guzzetta**, Department of Anesthesiology, Emory University School of Medicine, Atlanta, USA

Any comments on the article can be found at the end of the article.

Corresponding author: Nicoleta Stoicea (nicoleta.stoicea@osumc.edu)

Competing interests: The authors declare that they have no competing interests.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2017 Arias-Morales CE *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Arias-Morales CE, Stoicea N, Gonzalez-Zacarias AA *et al.* **Revisiting blood transfusion and predictors of outcome in cardiac surgery patients: a concise perspective [version 1; peer review: 2 approved]** F1000Research 2017, 6(F1000 Faculty Rev):168 <https://doi.org/10.12688/f1000research.10085.1>

First published: 20 Feb 2017, 6(F1000 Faculty Rev):168 <https://doi.org/10.12688/f1000research.10085.1>

Introduction

According to the National Blood Collection & Utilization Survey (NBCUS), blood transfusion rates, with the exception of platelet transfusions, decreased between 2008 and 2011¹. Specifically, there was an 8.2% decrease in red blood cell (RBC) transfusions as well as a 13.4% decrease in plasma transfusions. In the United States, however, cardiac surgery-related blood transfusion reached new highs in 2010, with 34% of patients receiving blood products². Cardiac surgeries generate the greatest need for blood transfusion, followed by orthopedic surgeries^{3,4}. Transfusion is often necessary in cardiac procedures to correct coagulopathy, blood loss, and hemodilution from pump priming⁵. Furthermore, patients undergoing cardiac surgeries are likely to have comorbidities such as anemia and history of myocardial infarction (MI), thereby increasing the risk of complications and blood transfusion requirement^{2,3,6}. It is important to note that the majority of cardiac surgery patients who are transfused and show a high morbidity and mortality receive approximately two units of blood^{3,7}. These patients are likely being treated for anemia and are otherwise hemodynamically stable⁷⁻⁹. However, patients in the high-risk subset, based on the European System for Cardiac Operative Risk Evaluation (EuroSCORE) >8, consumed blood products owing to hemorrhagic complications³. In light of this information, we reviewed the literature to assess the 30-day and 1-year morbidity and mortality outcomes in transfused patients who underwent complicated and uncomplicated coronary artery bypass grafting (CABG) surgery defined as the absence of postoperative complications by the Society of Thoracic Surgeons (STS).

Blood transfusion in critically ill patients

Anemia is a common complication in critically ill patients¹⁰. According to the World Health Organization (WHO), anemia is defined as a hemoglobin level of less than 13 g/dL in men and 12 g/dL in women¹¹. There is a complex relationship between RBC transfusions and clinical outcome in critically ill patients. The increased mortality seen in transfused patients might be attributed to a complex illness and might not be related to blood transfusion per se. Statistical measures controlling for mortality risk factors such as preoperative hematocrit, age, or comorbidities allow for presumably unbiased comparison between transfused and non-transfused groups¹².

Kulier *et al.*¹³ describe the problematic paradox faced by clinicians treating anemic patients undergoing CABG surgery. While the authors did not dispute that transfusion may be associated with a variety of complications previously reported in the literature, the authors' own investigation found a significant correlation between preoperative anemia and renal and central nervous system outcomes as well as in-hospital mortality. Increased cardiac adverse events were attributed to an interaction between preoperative anemia and other comorbidities. Thus, there is a paradox: should anemic patients, especially those with compromised compensatory cardiovascular mechanisms, be preoperatively transfused with RBCs, thus incurring one set of possible complications, or should these patients be transfused only during or after surgery as needed, risking the occurrence of another set of adverse events? Effort should always be made to correct anemia without transfusion prior to cardiac surgery, even in patients able to compensate for

their anemia with increased stroke volumes; however, a consensus on when hemoglobin levels indicate preoperative transfusion has yet to be firmly established¹³.

Generally, 95% of patients admitted to the intensive care unit (ICU) for more than 3 days develop anemia, resulting in multiple blood product transfusions¹⁴. It is estimated that 50% of these admitted ICU patients receive RBC transfusions during their stay^{15,16}. Furthermore, the proportion of patients transfused increases by 30% when the ICU length of stay (LOS) exceeds 7 days. These patients receive a mean of 9.5 units of blood products, and it is estimated that two-thirds of these transfusions are not related to acute blood loss^{10,16,17}.

Postoperative anemia is common after CABG surgery and is associated with a compromised cardiovascular outcome. The STS recommended a strict transfusion protocol¹⁸ for cardiac surgery patients with hemoglobin levels below 7 g/dL, with RBC transfusions being reasonable and lifesaving if the patient exhibits hemodynamic instability¹⁹.

Transfusion of RBCs has been recognized as a risk factor for adverse outcomes in cardiac surgery²⁰ and related to patient characteristics such as left ventricular ejection fraction (LVEF) <35%, age >70, preoperative hemoglobin <11 g/dL, insulin-dependent diabetes, emergency surgeries, female gender, impaired renal function (creatinine >1.6 mg/dL), and re-operation²¹. Pattakos *et al.*²² studied the outcome of patients undergoing cardiac surgery who refused transfusions owing to religious beliefs. The authors included 322 Jehovah's Witness patients and 87,453 non-Jehovah's Witness patients. They concluded that patients who refused transfusion had fewer acute complications and shorter length of stay, better 1-year survival, and similar 20-year survival when compared to transfused patients²³.

A retrospective study published by Dejam *et al.*¹² demonstrated that RBC transfusion improved outcomes in some patients and worsened the clinical course in patients with particular comorbidities, such as cirrhosis, congestive heart failure, diabetes, sepsis, respiratory disease, solid cancer, and hematologic cancer. However, considering that patients undergoing cardiac surgery are often critically ill, it may be difficult to establish the causation between transfusions and mortality.

Blood transfusion in uncomplicated cardiac patients

Few studies have recorded the effects of blood transfusions in anemic and non-anemic patients who are otherwise stable. A retrospective study carried out by the Cleveland Clinic found that non-anemic patients (hematocrit >25% during bypass) who received intraoperative blood transfusion for CPB surgery experienced longer ventilator support times, LOS, and decreased long-term survival when compared to non-anemic patients or untreated anemia patients²³. Blood transfusion in CABG patients with low- to moderate-risk profiles (EuroSCORE <8), postoperative hemoglobin >10 g/dL, minimal postoperative blood loss, and no preoperative morbidities within 24 hours of surgery posed a greater risk for postoperative cardiac events and infections when compared to those who did not receive any blood transfusion⁸.

Shaw *et al.*²⁴ retrospectively compared the effects of blood transfusion in a cohort stratified according to hematocrit values. The researchers recovered preoperative hematocrit data from transfused and non-transfused cardiac surgery patients. The authors reported a significantly higher 30-day mortality rate for the transfused group when compared with the non-transfused group. These results aligned with the existing evidence of increased mortality in transfused patients^{8,24–26}. Studies of blood transfusion in uncomplicated cardiac surgery allow a more objective evaluation of postoperative outcomes^{8,9,23,24,27} and indicate that stable transfused patients do not receive a benefit from this practice in terms of LOS, 30-day morbidity, and 1-year mortality^{24,27,28}.

A retrospective study published by Schwann *et al.* examined the association between transfusions and mortality among 6,947 patients who underwent CABG. The overall RBC transfusion rate was 33.9%. Postoperative complications were reported in 35.2% of the patients, specifically in patients who received RBC transfusion when compared with the uncomplicated group. The group reporting complications included older females with previous comorbidities. At 30-day and 5-year follow-up survival, the incidence of death was higher in transfused versus non-transfused patients. RBC transfusion increased the risk of long-term cardiac and non-cardiac mortality after CABG²⁹.

Blood transfusion in complicated cardiac patients

Blood transfusion is a common practice in complicated patients undergoing CABG surgery. Cardiac patients require higher rates of transfusions than do non-cardiac patients³⁰. Complicated patients generally present with advanced heart disease, co-existing diabetes mellitus, end-stage renal disease, or liver dysfunction, postoperative complications yielding a greater LOS and higher mortality rates³¹.

Cardiogenic shock (CS) is the primary cause of hospital death after acute MI (AMI). Operative mortality of patients who undergo CABG in the setting of AMI-CS ranges from 20% in isolated CABG to 33% in CABG plus valve surgery, reaching 58% in CABG plus ventricular septal repair³². Similarly, Acharya *et al.*³³ evaluated outcomes of 5,496 patients with AMI-CS undergoing non-elective CABG from 2005 to 2013. The authors found an intraoperative mortality of 18.1% for patients who received intraoperative blood products (65.2%) in 2013 when compared to 19.3% in 2005 ($p < 0.001$)³³.

Gundling *et al.* conducted an 8-year retrospective study and concluded that the necessity of blood product administration was increased in patients with liver cirrhosis undergoing cardiac surgery; the 30-day mortality rate was higher and long-term survival rate lower when compared to patients without liver cirrhosis³⁴.

Furthermore, recent reports have indicated worse outcomes when transfusion is due to preoperative anemia or blood dyscrasias^{33,34}. In 2014, Engoren *et al.* evaluated late mortality in 922 patients who underwent isolated CABG during a 3.5-year period. They found that patients with preoperative anemia who received intraoperative transfusion had an increased rate of death compared with those without anemia and transfusion³⁵. Similarly, Paone *et al.* concluded that most of the patients who died postoperatively

received blood transfusions and presented a prolonged and complicated postoperative evolution⁸. Additionally, patients diagnosed with immune thrombocytopenia (ITP) undergoing CABG surgery may require corticosteroid treatment before surgery in order to decrease intraoperative and postoperative bleeding. Jubelirer *et al.* reviewed cases of patients with ITP who underwent CABG. From 51 patients, 21 received platelet transfusion and 27 received RBCs intraoperatively. CABG was successfully performed in these patients without the need of preoperative splenectomy or prolongation of hospital stay³⁶.

Perioperative risk factors might affect the length of ICU stay. Generally, older cardiac surgery patients have longer ICU stays because of their existing comorbidities. Azafarin *et al.* determined in a cross-sectional study that cigarette smoking, opioid addiction, preoperative ejection fraction of $\leq 40\%$, and intraoperative blood transfusion are predictors for prolonged ICU stay and a higher rate of complications³¹.

Paone *et al.* used the predicted risk of mortality measures to confirm the hypothesis that preoperative profile played a more dominant role when considering mortality and transfusion rates in patients undergoing cardiac surgery⁸. Likewise, other studies have reported weak or no associations between transfusion and mortality^{7,37,38}. Koster *et al.*³⁹ in a single-center retrospective study demonstrated no association between the transfusion of one to two units of leucocyte-depleted RBCs and 30-day mortality in CABG patients. Haanschoten *et al.* found that patients with a baseline hemoglobin of ≥ 11.3 g/dL who underwent isolated CABG surgery without the availability of RBCs in the operating room presented a decrease in complications and LOS⁴⁰.

Shander also commented on the lack of temporality as a major weakness in this area of research and stated that cause and effect cannot be confirmed based on retrospective studies with unknown blood transfusion time and onset of complications⁹. Though certain complications may arise rapidly following transfusion, other adverse events may develop in the hours, days, and weeks after blood-product administration, making definitive causation more difficult. While in the former case close temporality provides evidence that transfusion was the impetus for the complication, adverse events which occur days or more after transfusion has concluded may be caused by the transfusion, surgical insult or drug administration, patient comorbidity, or antagonism of several factors. Moreover, transfusion threshold recommendations, despite the evidence-based guidelines, remain an indefinite parameter for blood transfusion; therefore, physicians must carefully deliberate the benefits and potential adverse effects when deciding to transfuse⁴¹.

Conclusion

The relationship between transfusion and clinical outcomes in cardiac patients undergoing complicated and uncomplicated CABG remains poorly understood, suggesting a complex interaction among various patient characteristics, demographics, type of procedure, patients' preoperative status, and the preferences of surgeons and anesthesiologists and may not be the result of transfusions per se. The increased mortality in transfused patients may

or may not be triggered by transfusion itself but rather the outcome of transfusion in a more complex perioperative experience. To better elucidate if and to what degree transfusion plays a role in patient complications following coronary procedures, prospective studies controlling for patient demographics and comorbidities, surgical and anesthesia parameters, and transfusion thresholds are needed. With other previously implicated factors excluded or controlled for, a more definitive consensus on transfusion as a causative factor for specific adverse events, which is lacking in the currently published literature, may be possible regardless of temporality. If transfusion is established as an independent factor for

complications, then interactions with other comorbidities and patient and surgical factors should be explored to identify those transfusion patients at highest risk for complication.

Competing interests

The authors declare that they have no competing interests.

Grant information

The author(s) declared that no grants were involved in supporting this work.

References

- US Department of Health and Human Services: **The 2011 national blood collection and utilization survey report**. Washington, DC: US Department of Health and Human Services, Office of the Assistant Secretary for Health. 2011; 15. [Reference Source](#)
- Robich MP, Koch CG, Johnston DR, *et al.*: **Trends in blood utilization in United States cardiac surgical patients**. *Transfusion*. 2015; 55(4): 805–14. [PubMed Abstract](#) | [Publisher Full Text](#)
- Geissler RG, Rotering H, Buddendick H, *et al.*: **Utilisation of blood components in cardiac surgery: a single-centre retrospective analysis with regard to diagnosis-related procedures**. *Transfus Med Hemother*. 2015; 42(2): 75–82. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Stoicescu N, Bergese SD, Ackermann W, *et al.*: **Current status of blood transfusion and antifibrinolytic therapy in orthopedic surgeries**. *Front Surg*. 2015; 2: 3. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Koch CG: **Tolerating anemia: taking aim at the right target before pulling the transfusion trigger**. *Transfusion*. 2014; 54(10 Pt 2): 2595–7. [PubMed Abstract](#) | [Publisher Full Text](#)
- F** Ad N, Massimiano PS, Burton NA, *et al.*: **Effect of patient age on blood product transfusion after cardiac surgery**. *J Thorac Cardiovasc Surg*. 2015; 150(1): 209–14. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- F** Paone G, Likosky DS, Brewer R, *et al.*: **Transfusion of 1 and 2 units of red blood cells is associated with increased morbidity and mortality**. *Ann Thorac Surg*. 2014; 97(1): 87–93; discussion 93–4. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- F** Paone G, Herbert MA, Theurer PF, *et al.*: **Red blood cells and mortality after coronary artery bypass graft surgery: an analysis of 672 operative deaths**. *Ann Thorac Surg*. 2015; 99(5): 1583–9; discussion 1589–90. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Shander A, Goodnough LT: **Can blood transfusion be not only ineffective, but also injurious?** *Ann Thorac Surg*. 2014; 97(1): 11–4. [PubMed Abstract](#) | [Publisher Full Text](#)
- Vincent JL, Baron JF, Reinhart K, *et al.*: **Anemia and blood transfusion in critically ill patients**. *JAMA*. 2002; 288(12): 1499–507. [PubMed Abstract](#) | [Publisher Full Text](#)
- Ania BJ, Suman VJ, Fairbanks VF, *et al.*: **Incidence of anemia in older people: an epidemiologic study in a well defined population**. *J Am Geriatr Soc*. 1997; 45(7): 825–31. [PubMed Abstract](#) | [Publisher Full Text](#)
- F** Dejam A, Malley BE, Feng M, *et al.*: **The effect of age and clinical circumstances on the outcome of red blood cell transfusion in critically ill patients**. *Crit Care*. 2014; 18(4): 487. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- F** Kulier A, Levin J, Moser R, *et al.*: **Impact of preoperative anemia on outcome in patients undergoing coronary artery bypass graft surgery**. *Circulation*. 2007; 116(5): 471–9. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Rodriguez RM, Corwin HL, Gettinger A, *et al.*: **Nutritional deficiencies and blunted erythropoietin response as causes of the anemia of critical illness**. *J Crit Care*. 2001; 16(1): 36–41. [PubMed Abstract](#) | [Publisher Full Text](#)
- Corwin HL, Parsonnet KC, Gettinger A: **RBC transfusion in the ICU. Is there a reason?** *Chest*. 1995; 108(3): 767–71. [PubMed Abstract](#) | [Publisher Full Text](#)
- Littenberg B, Corwin H, Gettinger A, *et al.*: **A practice guideline and decision aid for blood transfusion**. *Immunohematology*. 1995; 11(3): 88–94. [PubMed Abstract](#)
- F** Lako A, Bilali S, Memishaj S, *et al.*: **The impact of blood use on patients undergoing coronary artery bypass surgery: a prospective study**. *G Chir*. 2014; 35(1–2): 20–6. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Westenbrink BD, Kleijn L, de Boer RA, *et al.*: **Sustained postoperative anaemia is associated with an impaired outcome after coronary artery bypass graft surgery: insights from the IMAGINE trial**. *Heart*. 2011; 97(19): 1590–6. [PubMed Abstract](#) | [Publisher Full Text](#)
- F** Patel NN, Avlonitis VS, Jones HE, *et al.*: **Indications for red blood cell transfusion in cardiac surgery: a systematic review and meta-analysis**. *Lancet Haematol*. 2015; 2(12): e543–53. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- F** Murphy GJ, Reeves BC, Rogers CA, *et al.*: **Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery**. *Circulation*. 2007; 116(22): 2544–52. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Litmathe J, Boeken U, Feindt P, *et al.*: **Predictors of homologous blood transfusion for patients undergoing open heart surgery**. *Thorac Cardiovasc Surg*. 2003; 51(1): 17–21. [PubMed Abstract](#) | [Publisher Full Text](#)
- F** Pattakos G, Koch CG, Brizzio ME, *et al.*: **Outcome of patients who refuse transfusion after cardiac surgery: a natural experiment with severe blood conservation**. *Arch Intern Med*. 2012; 172(15): 1154–60. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- F** Loor G, Li L, Sabik JF 3rd, *et al.*: **Nadir hematocrit during cardiopulmonary bypass: end-organ dysfunction and mortality**. *J Thorac Cardiovasc Surg*. 2012; 144(3): 654–662.e4. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Shaw RE, Johnson CK, Ferrari G, *et al.*: **Balancing the benefits and risks of blood transfusions in patients undergoing cardiac surgery: a propensity-matched analysis**. *Interact Cardiovasc Thorac Surg*. 2013; 17(1): 96–102. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Kuduvallu M, Oo AY, Newall N, *et al.*: **Effect of peri-operative red blood cell transfusion on 30-day and 1-year mortality following coronary artery bypass surgery**. *Eur J Cardiothorac Surg*. 2005; 27(4): 592–8. [PubMed Abstract](#) | [Publisher Full Text](#)
- Engoren MC, Habib RH, Zacharias A, *et al.*: **Effect of blood transfusion on long-term survival after cardiac operation**. *Ann Thorac Surg*. 2002; 74(4): 1180–6. [PubMed Abstract](#) | [Publisher Full Text](#)
- Möhle P, Snyder-Ramos SA, Miao Y, *et al.*: **Postoperative red blood cell transfusion and morbid outcome in uncomplicated cardiac surgery patients**. *Intensive Care Med*. 2011; 37(1): 97–109. [PubMed Abstract](#) | [Publisher Full Text](#)
- Loor G, Rajeswaran J, Li L, *et al.*: **The least of 3 evils: exposure to red blood cell transfusion, anemia, or both?** *J Thorac Cardiovasc Surg*. 2013; 146(6): 1480–1487.e6. [PubMed Abstract](#) | [Publisher Full Text](#)
- F** Schwann TA, Habib JR, Khalifeh JM, *et al.*: **Effects of Blood Transfusion on Cause-Specific Late Mortality After Coronary Artery Bypass Grafting-Less Is More**. *Ann Thorac Surg*. 2016; 102(2): 465–73. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)

30. Du Pont-Thibodeau G, Harrington K, Lacroix J: **Anemia and red blood cell transfusion in critically ill cardiac patients.** *Ann Intensive Care.* 2014; 4: 16.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
31. **F** Azarfarin R, Ashouri N, Totonchi Z, *et al.*: **Factors influencing prolonged ICU stay after open heart surgery.** *Res Cardiovasc Med.* 2014; 3(4): e20159.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
32. **F** Mehta RH, Grab JD, O'Brien SM, *et al.*: **Clinical characteristics and in-hospital outcomes of patients with cardiogenic shock undergoing coronary artery bypass surgery: insights from the Society of Thoracic Surgeons National Cardiac Database.** *Circulation.* 2008; 117(7): 876–85.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
33. **F** Acharya D, Gulack BC, Loyaga-Rendon RY, *et al.*: **Clinical Characteristics and Outcomes of Patients With Myocardial Infarction and Cardiogenic Shock Undergoing Coronary Artery Bypass Surgery: Data From The Society of Thoracic Surgeons National Database.** *Ann Thorac Surg.* 2016; 101(2): 558–66.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
34. Gundling F, Seidl H, Gansera L, *et al.*: **Early and late outcomes of cardiac operations in patients with cirrhosis: a retrospective survival-rate analysis of 47 patients over 8 years.** *Eur J Gastroenterol Hepatol.* 2010; 22(12): 1466–73.
[PubMed Abstract](#)
35. **F** Engoren M, Schwann TA, Habib RH, *et al.*: **The independent effects of anemia and transfusion on mortality after coronary artery bypass.** *Ann Thorac Surg.* 2014; 97(2): 514–20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
36. Jubelirer SJ, Mousa L, Reddy U, *et al.*: **Coronary artery bypass grafting (CABG) in patients with immune thrombocytopenia (ITP): a community hospital experience and review of the literature.** *W V Med J.* 2011; 107(6): 10–4.
[PubMed Abstract](#)
37. Engoren M, Arslanian-Engoren C: **Long-term survival in the intensive care unit after erythrocyte blood transfusion.** *Am J Crit Care.* 2009; 18(2): 124–31; quiz 132.
[PubMed Abstract](#) | [Publisher Full Text](#)
38. Vamvakas EC, Carven JH: **RBC transfusion and postoperative length of stay in the hospital or the intensive care unit among patients undergoing coronary artery bypass graft surgery: the effects of confounding factors.** *Transfusion.* 2000; 40(38): 832–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
39. **F** Koster A, Zittermann A, Borgermann J, *et al.*: **Transfusion of 1 and 2 units of red blood cells does not increase mortality and organ failure in patients undergoing isolated coronary artery bypass grafting.** *Eur J Cardiothorac Surg.* 2016; 49(3): 931–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
40. **F** Haanschoten MC, van Straten AH, Verstappen F, *et al.*: **Reducing the immediate availability of red blood cells in cardiac surgery, a single-centre experience.** *Neth Heart J.* 2015; 23(1): 28–32.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
41. Ferraris VA: **Blood transfusion in cardiac surgery: who should get transfused?** *Lancet Haematol.* 2015; 2(12): e510–1.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. **Nina A Guzzetta**

Department of Anesthesiology, Emory University School of Medicine, Atlanta, USA

Competing Interests: No competing interests were disclosed.

2. **Fausto Biancari**

Department of Surgery, Oulu University Hospital, Oulu, Finland

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research